Long-term safety and efficacy of ziv-aflibercept in retinal diseases
| Autor: | Abdulrazzak Charbaji, Jay Chhablani, Ahmad M. Mansour, Chintan J Dedhia, Ahmed Souka, Mohammed Ashraf |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Visual acuity genetic structures Recombinant Fusion Proteins Visual Acuity Paired comparison Angiogenesis Inhibitors Spectral domain Macular Edema 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Retinal Diseases medicine Humans Ocular inflammation Aged Aflibercept Aged 80 and over business.industry Outcome measures Retinal Middle Aged eye diseases Sensory Systems Surgery Ophthalmology Receptors Vascular Endothelial Growth Factor chemistry Intravitreal Injections 030221 ophthalmology & optometry Female Long term safety medicine.symptom business Tomography Optical Coherence 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | British Journal of Ophthalmology. 101:1374-1376 |
| ISSN: | 1468-2079 0007-1161 |
| DOI: | 10.1136/bjophthalmol-2016-309724 |
| Popis: | To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept.Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three centres. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution (logMar)) and central macular thickness (CMT) on spectral domain optical coherence tomography and monitoring for ocular inflammation, progression of lens opacities and intraocular pressure rise. Paired comparison was done using Wilcoxon signed-rank test calculator.Sixty-five eyes of 60 consecutive patients received a mean of 8.4 (6-17) intravitreal injections with a baseline mean logMAR BCVA of 0.98±0.56 and CMT 432.7±163.0 μm and followed for a mean of 9.2 months (range 6-18 months). After the sixth injection, mean BCVA improved to 0.57±0.36 (p=0.001) and CMT decreased to 274.8±117.8 μm (p=0.0001). At the 9-month follow-up, mean BCVA improved to 0.62±0.37 (p=0.0004) and mean CMT decreased to 292.0±160.9 μm (p0.01) in 19 eyes. At 1 year, mean BCVA was 0.73±0.52 and CMT 311.6±232.5 μm in seven eyes. Intraocular pressures did not increase after injections. One subject developed transient mild iritis at the fourth injection but not on subsequent injections. No lens opacity progression or endophthalmitis was noted. Systemic adverse effects were not registered.Repeated intravitreal injections of ziv-aflibercept appear tolerable, safe and efficacious in the therapy of retinal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|